Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,530Revenue $M4.1Net Margin (%)-3,969.3Z-Score25.8
Enterprise Value $M1,306EPS $-1.0Operating Margin %-4,122.2F-Score5
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-3,969.3Higher ROA y-yY
Price/Book6.410-y EBITDA Growth Rate %0Quick Ratio10.6Cash flow > EarningsY
Price/Sales5695-y EBITDA Growth Rate %0Current Ratio10.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-38.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-42.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M89.6ROI % (ttm)-48.8Gross Margin Increase y-yY

Gurus Latest Trades with CLDX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CLDXJean-Marie Eveillard 2014-09-30 Buy 0.01%$12.05 - $17.57
($14.51)
$ 17.0818%New holding, 250000 sh.250,000
CLDXJean-Marie Eveillard 2014-03-31 Sold Out -0.01%$16.95 - $31.59
($25.6)
$ 17.08-33%Sold Out0
CLDXAndreas Halvorsen 2013-12-31 Sold Out -0.13%$21.51 - $36.71
($25.51)
$ 17.08-33%Sold Out0
CLDXJean-Marie Eveillard 2013-12-31 Reduce-0.04%$21.51 - $36.71
($25.51)
$ 17.08-33%Reduce -75.45%135,000
CLDXAndreas Halvorsen 2013-09-30 Buy 0.13%$18.37 - $36.01
($22.76)
$ 17.08-25%New holding, 672513 sh.672,513
CLDXJean-Marie Eveillard 2013-06-30 Reduce-0.02%$11.01 - $16.09
($13.13)
$ 17.0830%Reduce -45.89%665,560
CLDXJean-Marie Eveillard 2012-06-30 Add0.02%$3.9 - $5.26
($4.39)
$ 17.08289%Add 260.87%1,660,000
CLDXGeorge Soros 2012-06-30 Sold Out -0.06%$3.9 - $5.26
($4.39)
$ 17.08289%Sold Out0
CLDXGeorge Soros 2012-03-31 Buy 0.06%$2.77 - $5.46
($4)
$ 17.08327%New holding, 803200 sh.803,200
CLDXJean-Marie Eveillard 2012-03-31 Add0.01%$2.77 - $5.46
($4)
$ 17.08327%Add 360%460,000
CLDXJean-Marie Eveillard 2011-12-31 Reduce$2.11 - $3.21
($2.7)
$ 17.08533%Reduce -71.43%100,000
CLDXJean-Marie Eveillard 2011-06-30 Buy 0.01%$3.03 - $4.46
($3.75)
$ 17.08356%New holding, 350000 sh.350,000
CLDXJean-Marie Eveillard 2010-03-31 Sold Out $4.35 - $6.39
($4.93)
$ 17.08246%Sold Out0
CLDXJean-Marie Eveillard 2009-12-31 Buy $4.2 - $5.66
($4.78)
$ 17.08257%New holding, 100000 sh.100,000
CLDXJean-Marie Eveillard 2009-09-30 Sold Out $4.95 - $7.93
($6.35)
$ 17.08169%Sold Out0
CLDXJean-Marie Eveillard 2009-06-30 Buy $6.81 - $11.22
($8.56)
$ 17.08100%New holding, 50000 sh.50,000
CLDXJohn Hussman 2009-06-30 Sold Out $6.81 - $11.22
($8.56)
$ 17.08100%Sold Out0
CLDXJohn Hussman 2008-12-31 Buy $4.94 - $7.81
($6.3)
$ 17.08171%New holding, 13000 sh.13,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CLDX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CLDX Jean-Marie Eveillard 2014-09-30250,0000.280.01New Buy
Premium Most recent portfolio changes are included for Premium Members only!


CLDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
van den Broek RichardDirector 2014-12-17Sell0$0view
CATLIN AVERY WSr. VP & CFO 2013-12-06Sell183,333$24.5-30.29view
ELLBERGER LARRYDirector 2013-12-06Sell17,728$24.5-30.29view
PENNER HARRY JRDirector 2013-12-06Sell17,728$24.5-30.29view
LIPTON KAREN SHOOSDirector 2013-12-06Sell17,728$24.5-30.29view
KELER TIBORSr. VP & CSO 2011-08-11Buy5,000$2.5583.2view
Marucci Anthony SPresident & CEO 2011-08-09Buy15,000$2.41608.71view
CATLIN AVERY WSr. VP & CFO 2011-08-09Buy2,000$2.39614.64view
Davis Thomas AndrewSr. VP & CMO 2010-09-16Buy2,500$3.77353.05view
LIPTON KAREN SHOOSDirector 2010-09-16Buy3,000$3.74356.68view

Press Releases about CLDX :

    Quarterly/Annual Reports about CLDX:

    News about CLDX:

    Articles On GuruFocus.com
    CLDX up 223%, Cohen Gains Big Apr 23 2013 
    Steve Cohen Increases Celldex Up 145% Apr 06 2013 
    comment on CLDX Mar 06 2013 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
    Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
    CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 
    CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) May 06 2010 
    cooldecency99 note on CLDX May 01 2010 
    CELLDEX THERAPEUTICS, INC (CLDX) CFO Avery W Catlin buys 1,000 Shares Dec 01 2009 

    More From Other Websites
    Six Biotech and Technology Stocks With Strong Technical Set-Ups Dec 18 2014
    Celldex Therapeutics Announces Appointment to Board of Directors Dec 18 2014
    CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Dec 18 2014
    Celldex Therapeutics Announces Appointment to Board of Directors Dec 18 2014
    Celldex Announces Completion of Enrollment in Phase 3 Study of Rindopepimut in Frontline... Dec 15 2014
    Celldex's Glembatumumab Vedotin in Phase II for Melanoma Dec 05 2014
    Celldex Therapeutics Initiates a Phase 2 Study of Glembatumumab Vedotin in Patients with Advanced... Dec 04 2014
    Celldex Therapeutics Initiates a Phase 2 Study of Glembatumumab Vedotin in Patients with Advanced... Dec 04 2014
    Here's The Latest Biotech Breakout Nov 26 2014
    Celldex Therapeutics (CLDX) Stock Rises Today on High Volume Nov 20 2014
    Celldex Therapeutics Surges on Positive Rindopepimut Data Nov 18 2014
    Mid-Day Losers From November 18: Omega Protein, Urban Outfitters, Celldex Therapeutics, Amicus... Nov 18 2014
    Celldex Therapeutics (CLDX) Stock Sells Off Today Following Monday's Gains Nov 18 2014
    Perilous Reversal Stock: Celldex Therapeutics (CLDX) Nov 18 2014
    Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% Nov 18 2014
    DreamWorks lower, Hasbro higher after talks stall Nov 17 2014
    Street Talk: Marriott downgrade Nov 17 2014
    Midday Gainers From November 17: Celldex Therapeutics, Amicus Therapeutics, Baker Hughes, Allergan Nov 17 2014
    Celldex Therapeutics (CLDX) Stock Surges Following Brain Tumor Immunotherapy Results Nov 17 2014
    Celldex Therapeutics Jumps 25% Amid Brain Cancer Study Nov 17 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK